CD8A and melanoma: In melanoma mice, subcutaneous doxorubicin treatment increased CD8+ T cell infiltration, enhanced secretion of IFN-γ, granzyme B, and perforin, activated B cells and DC, promoted HEV, and induced TLS formation, surpassing the effects of non-ICD drugs and combination therapy (102).